jnj-7777120 and Triple-Negative-Breast-Neoplasms

The aim of this work was to improve the knowledge of the role of histamine in breast cancer by assessing the therapeutic efficacy of histamine and histamine H4 receptor (H4R) ligands in a triple-negative breast cancer (TNBC) model developed in immunocompetent hosts. By using publicly available genomic data, we further investigated whether histidine decarboxylase (HDC) could be a potential biomarker.. Tumours of 4T1 TNBC cells were orthotopically established in BALB/c mice. Treatments employed (mg kg. Increased HDC gene expression is associated with better relapse-free and overall survival in breast cancer patients. Histamine treatment (5 mg kg. Histamine plays a complex role and stands out as a promising drug for TNBC treatment, which deserves to be tested in clinical settings. HDC expression level is associated with clinicopathological characteristics, suggesting a prognostic value in breast cancer.

Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Factual; Female; Histamine; Histamine Agonists; Histamine Antagonists; Histidine Decarboxylase; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Knockout; Oximes; Piperazines; Prognosis; Receptors, Histamine H4; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays